Literature DB >> 9450141

Anti-interleukin (IL)-4 and -IL-5 antibodies downregulate IgE and eosinophilia in mice exposed to Aspergillus antigens.

V P Kurup1, P S Murali, J Guo, H Choi, B Banerjee, J N Fink, R L Coffman.   

Abstract

The effect of multiple divided doses compared with single-dose injections of antibodies to murine interleukin (IL)-4 and IL-5 in their respective downregulation of IgE and eosinophilia developing in a model of allergic aspergillosis is investigated. BALB/c mice were exposed to Aspergillus fumigatus antigens (Af) before and along with anticytokine antibodies. The kinetics of blood eosinophils, eosinophil peroxidase (EPO) in bone-marrow cells, serum levels of IgE and Af-specific antibodies, Af-induced cytokine production and mRNA, and lung histology were studied. The results indicate that only multiple anti-IL-5 antibodies were effective in maintaining baseline levels of blood eosinophils. Multiple anti-IL-4 antibodies also downregulated eosinophils in the bone marrow, lung, and peripheral blood, although to a lesser extent than in anti-IL-5 antibody-injected mice. Significant correlation between the EPO activity and the eosinophil numbers in anticytokine antibody-treated mice was observed. The different anti-IL-4 antibody treatments downregulated IgE to the same extent. We conclude that multiple divided doses of anti-IL-5 antibodies are required to sustain normal eosinophil levels in murine allergic aspergillosis. This information may be significant in the therapy of pulmonary allergic diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9450141     DOI: 10.1111/j.1398-9995.1997.tb02526.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  9 in total

1.  Effect of a CD4-depleting antibody on the development of Cryptococcus neoformans-induced allergic bronchopulmonary mycosis in mice.

Authors:  Shikha Arora; Roderick A McDonald; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 2.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

3.  Evolution of the Immune Response to Chronic Airway Colonization with Aspergillus fumigatus Hyphae.

Authors:  Mirjam Urb; Brendan D Snarr; Gabriella Wojewodka; Mélanie Lehoux; Mark J Lee; Benjamin Ralph; Maziar Divangahi; Irah L King; Toby K McGovern; James G Martin; Richard Fraser; Danuta Radzioch; Donald C Sheppard
Journal:  Infect Immun       Date:  2015-06-29       Impact factor: 3.441

Review 4.  Animal models of allergic bronchopulmonary aspergillosis.

Authors:  Viswanath P Kurup; Gabriele Grunig
Journal:  Mycopathologia       Date:  2002       Impact factor: 2.574

Review 5.  Immune regulation during allergic bronchopulmonary mycosis: lessons taught by two fungi.

Authors:  Shikha Arora; Gary B Huffnagle
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

6.  Distinct CD4+-T-cell responses to live and heat-inactivated Aspergillus fumigatus conidia.

Authors:  Amariliz Rivera; Heather L Van Epps; Tobias M Hohl; Gabrielle Rizzuto; Eric G Pamer
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

7.  Modulation of airway inflammation by immunostimulatory CpG oligodeoxynucleotides in a murine model of allergic aspergillosis.

Authors:  Banani Banerjee; Kevin J Kelly; Jordan N Fink; James D Henderson; Naveen K Bansal; Viswanath P Kurup
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Prophylactic and Therapeutic Potential of Asp f1 Epitopes in Naïve and Sensitized BALB/c Mice.

Authors:  Neelkamal Chaudhary; Lakshna Mahajan; Taruna Madan; Anil Kumar; Gajendra Pratap Singh Raghava; Seturam Bandacharya Katti; Wahajul Haq; Puranam Usha Sarma
Journal:  Immune Netw       Date:  2009-10-30       Impact factor: 6.303

9.  Role of germination in murine airway CD8+ T-cell responses to Aspergillus conidia.

Authors:  Steven P Templeton; Amanda D Buskirk; Brandon Law; Brett J Green; Donald H Beezhold
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.